Anthem Biosciences Limited was originally incorporated as ‘Anthem Biosciences Private Limited’ under the provisions of the Companies Act, 1956, pursuant to a certificate of incorporation dated June 13, 2006, issued by RoC. Subsequently, the company was converted from a private company to a public company, pursuant to a board resolution dated October 18, 2024 and a resolution passed in the extraordinary general meeting of its Shareholders held on October 18, 2024 following which the name of the company was changed to ‘Anthem Biosciences Limited’ and a certificate of incorporation consequent upon conversion to public limited company was issued by the RoC on December 10, 2024.

The company is an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing with integrated New Chemical Entity (NCE) and New Biological Entity (NBE) capabilities across drug discovery, development, and commercial manufacturing. It provides end to end CRDMO services and it serves a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally. 

Its CRDMO platform comprises main modalities (RNAi, ADC, peptides, lipids and oligonucleotides) and manufacturing capabilities (custom synthesis, flow chemistry, fermentation and biotransformation). It derives revenue primarily from its CRDMO services, including developmental and commercial manufacturing, and research and development services. It also generates revenue from the manufacture and sale of specialty ingredients.

Business area of the company

Anthem Biosciences has been set up as a Life sciences/ Biotechnology based venture specialising in the manufacture of catalytic preparation, other organic compounds such as speciality organic molecules, biologically active peptides etc., which are high-value products used in drug, agrochemical and speciality chemicals industries. 

Awards, accreditations, and recognition

• 2023: Received a certificate of recognition as a ‘Four Star Export House’ from the Ministry of Commerce and Industry.
• 2023: Received an accreditation from AAALAC International.
• 2023: Received the Bureau Veritas Certification for achieving the ISO 9001:2015, ISO 14001:2015 & ISO 45001:2018 standards.
• 2024: Received the certification as a foreign drug manufacturer issued by the Minister of Health, Labour and Welfare.
• 2024: Received the ‘Pharma Excellence Award’ for excellence in contribution towards sustainability issued by ASSOCHAM.
• 2025: Received a certificate of appreciation in recognition of appreciable achievement in occupation safety and health during 2021-2023 from the National Safety Council of India Safety Awards - 2024.
• 2025: Received the State Level safety award under the category of Best Large Scale Industry.

History and milestones

• 2006: Incorporation of the company.
• 2007: Commenced operations of the company at Unit I and set up a custom synthesis plant with a capacity of 6 KL.
• 2008: Commencement of the discovery biology services with a fermentation capacity of 2 KL.
• 2010: Expanded the custom synthesis plant set up at Unit I increasing its capacity from 6 KL to 24 KL.
• 2013: Received the first USFDA audit approval for Unit I.
• 2016: Set up a high potent lab at Unit I - Bommasandra Facility.
• 2017: The company, pursuant to an order dated November 30, 2017, amalgamated with Anthem Cellutions (India) Private Limited by way of an acquisition of 100% of its share capital.
• 2017: Set up a solid phase peptide synthesis GMP lab with a capacity of 6 KL at Unit 1.
• 2017: Commenced operations of the Company at Unit II and set up an automated GMP compliant custom synthesis plant with a capacity of 128 KL and a fermentation plant with a capacity of 80 KL.
• 2017: Received the second USFDA audit approval for Unit I.
• 2018: Anthem Cellutions (India) Private Limited amalgamated into the company.
• 2019: Received the third USFDA approval for Unit I.
• 2019: Set up a flow chemistry lab at Unit I.
• 2020: Commenced operations in biological facility 2 earmarked for a specific client.
• 2022: Expanded the custom synthesis plant set up at Unit II increasing its capacity to 246 KL.
• 2023: Received the first USFDA audit approval and first therapeutic goods administration audit for Unit II.
• 2023: Addition of Oligonucleotide lab in Unit I.
• 2023: Set a cGMP scale continuous flow manufacturing facility for Unit II.
• 2024: Received the: second USFDA audit approval for Unit II; first ANVISA audit approval for Unit I; and first ANVISA audit approval for Unit II.
• 2024: Commenced operations of Neoanthem Lifesciences Private Limited, at Unit III designed as a chemistry lab and customer synthesis pilot plant for development, technology transfer and scale-up projects.
• 2024: Fermentation capacity expanded to 140 KL at Unit II.
• 2024: Conversion of the Company into a public limited company, under the name ‘Anthem Biosciences Limited’.
• 2025: Received the fourth USFDA approval for Unit I.